These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 12828083)

  • 1. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C.
    Kaito M; Yasui-Kawamura N; Iwasa M; Kobayashi Y; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
    Hepatogastroenterology; 2003; 50(51):775-8. PubMed ID: 12828083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus.
    Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S; Kawase I; Nakamura H
    Hepatogastroenterology; 2003; 50(54):2112-6. PubMed ID: 14696476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H; Ogawa H; Kuroda T; Yamamoto M; Enomoto H; Kishima Y; Yoshida K; Ito H; Matsuda M; Noguchi S
    Hepatogastroenterology; 2002; 49(47):1373-6. PubMed ID: 12239945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
    Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C.
    Nakamura H; Uyama H; Enomoto H; Kishima Y; Yamamoto M; Yoshida K; Okuda Y; Hirotani T; Kuroda T; Ito H; Matsuda M; Terabayashi M; Noguchi S
    Hepatogastroenterology; 2003; 50(49):222-6. PubMed ID: 12630027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C.
    Fukutomi T; Fukutomi M; Iwao M; Watanabe H; Tanabe Y; Hiroshige K; Kinukawa N; Nakamuta M; Nawata H
    Med Sci Monit; 2000; 6(4):692-8. PubMed ID: 11208393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of natural BALL-1 interferon-alpha treatment for patients with chronic hepatitis C and a possible enhancing effect of a twice-daily starting regimen with interferon-beta.
    Ebinuma H; Saito H; Tada S; Nakamoto N; Kurita S; Kitamaura K; Horikawa H; Kumagai N; Tsuchimoto K; Ishii H; Hibi T;
    Hepatogastroenterology; 2006; 53(67):94-9. PubMed ID: 16506384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-term interferon therapy for chronic hepatitis C patients with low viral load.
    Sato Y; Tokuue H; Kawamura N; Nezu-Yajima S; Nakajima H; Ishida H; Takahashi S
    Hepatogastroenterology; 2004; 51(58):968-72. PubMed ID: 15239226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load.
    Arase Y; Ikeda K; Tsubota A; Suzuki Y; Saitoh S; Kobayashi M; Kobayashi M; Suzuki F; Akuta N; Someya T; Kumada H
    J Gastroenterol; 2003; 38(2):158-63. PubMed ID: 12640530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial daily interferon administration can gain more eradication of HCV-RNA in patients with chronic hepatitis C, especially with serum intermediate viral load.
    Nakamura H; Ito H; Ogawa H; Takeda A; Kanazawa S; Kuroda T; Yamamoto M; Enomoto H; Kimura Y; Zenda S; Terabayashi M; Saeki K; Noguchi S; Hara H; Uemiya M; Igarashi A; Hayashi E
    Hepatogastroenterology; 1999; 46(26):1131-9. PubMed ID: 10370680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of hepatitis C virus serotype on the response of patients with chronic hepatitis C to interferon treatment].
    Chen LJ; Li MH; Xie Y; Xu DZ
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Jun; 21(2):117-9. PubMed ID: 17653309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: a multicenter randomized trial.
    Nakamura H; Ito H; Kimura Y; Takeda A; Ogawa H; Kanazawa S; Kuroda T; Inada M; Harada H; Kishimoto T; Zenda S; Terabayashi M; Saeki K; Wada M; Igarashi A; Uemiya M; Kobayashi Y; Hayashi E
    Hepatogastroenterology; 1998; 45(22):1045-55. PubMed ID: 9756005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of two interferon alfa treatment regimens characterized by an early virological response in patients with chronic hepatitis C.
    Kagawa T; Hosoi K; Takashimizu S; Kawazoe K; Mochizuki K; Wasada M; Nagata N; Uchiyama J; Nakano A; Nishizaki Y; Watanabe N; Matsuzaki S
    Am J Gastroenterol; 1998 Feb; 93(2):192-6. PubMed ID: 9468240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon.
    Montalto G; Tripi S; Cartabellotta A; Fulco M; Soresi M; Di Gaetano G; Carroccio A; Levrero M
    Am J Gastroenterol; 1998 Jun; 93(6):950-3. PubMed ID: 9647026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is interferon-alpha therapy safe and effective for patients with chronic hepatitis C and inflammatory bowel disease? A case-control study.
    Bargiggia S; Thorburn D; Anderloni A; Ardizzone S; Giorgi A; Bianchi Porro G; Parente F
    Aliment Pharmacol Ther; 2005 Aug; 22(3):209-15. PubMed ID: 16091058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-alpha therapy within the first year after acute hepatitis C infection in hemodialysis patients: efficacy and tolerance.
    Rocha CM; Perez RM; Narciso JL; Ferreira AP; Lemos LB; Medina-Pestana JO; Silva AE; Ferraz ML
    Eur J Gastroenterol Hepatol; 2007 Feb; 19(2):119-23. PubMed ID: 17272996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A trial of new interferon therapy for the patients with chronic hepatitis C resistant to interferon therapy].
    Arase Y; Kumada H
    Nihon Rinsho; 2001 Jul; 59(7):1309-14. PubMed ID: 11494543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM; Sheen IS; Liaw YF
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus RNA load in relapsed patients: week two of treatment is the best time to predict the complete response.
    Halfon P; Khiri H; Tran A; Pénaranda G; Courcambeck J; Joly H; Ouzan D
    Eur J Gastroenterol Hepatol; 2003 Oct; 15(10):1067-71. PubMed ID: 14501613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.